|
EP3640375A3
(en)
|
2012-12-11 |
2020-07-29 |
Albert Einstein College of Medicine |
Methods for high throughput receptor/ligand identification
|
|
PT3172227T
(pt)
*
|
2014-07-21 |
2019-12-06 |
Delinia Inc |
Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis
|
|
SI3482766T1
(sl)
|
2014-08-11 |
2020-09-30 |
Delinia, Inc. |
Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
KR20240115933A
(ko)
*
|
2016-05-04 |
2024-07-26 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
BR112018073606A2
(pt)
|
2016-05-18 |
2019-02-26 |
Cue Biopharma, Inc. |
polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
|
|
WO2017201131A1
(en)
|
2016-05-18 |
2017-11-23 |
Albert Einstein College Of Medicine, Inc. |
Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
CA3041334A1
(en)
|
2016-11-08 |
2018-05-17 |
Delinia, Inc. |
Il-2 variants for the treatment of autoimmune diseases
|
|
JP7228515B2
(ja)
*
|
2016-12-13 |
2023-02-24 |
デリニア，インコーポレーテッド |
多価制御性ｔ細胞調節因子
|
|
WO2018119114A1
(en)
|
2016-12-22 |
2018-06-28 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP3596118B1
(en)
|
2017-03-15 |
2024-08-21 |
Cue Biopharma, Inc. |
Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
|
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
CN110678550B
(zh)
*
|
2017-03-29 |
2023-11-14 |
国立大学法人宫崎大学 |
长效肾上腺髓质素衍生物
|
|
US10676516B2
(en)
|
2017-05-24 |
2020-06-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
EP3713592A4
(en)
|
2017-11-21 |
2022-01-12 |
The Board of Trustees of the Leland Stanford Junior University |
INTERLEUKIN-2 PARTIAL AGONISTS
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MX2020005208A
(es)
*
|
2017-12-06 |
2020-08-20 |
Pandion Operations Inc |
Muteinas de interleucina 2 (il-2) y usos de estas.
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
IL275426B2
(en)
|
2017-12-19 |
2025-03-01 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
CA3086842A1
(en)
|
2017-12-27 |
2019-07-04 |
Kyowa Kirin Co., Ltd. |
Il-2 variant
|
|
EP3737689A4
(en)
|
2018-01-09 |
2021-12-01 |
Cue Biopharma, Inc. |
MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
JP7534215B2
(ja)
|
2018-01-24 |
2024-08-14 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
|
WO2019144309A1
(en)
*
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
|
BR112020018709A2
(pt)
|
2018-03-28 |
2021-01-05 |
Bristol-Myers Squibb Company |
Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
|
|
EP3552738B1
(en)
*
|
2018-04-12 |
2024-07-31 |
Sandvik Machining Solutions AB |
A method of producing an additive manufactured object
|
|
CN120349426A
(zh)
|
2018-06-22 |
2025-07-22 |
科优基因公司 |
白介素-2变体及其使用方法
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
RU2021105821A
(ru)
|
2018-08-06 |
2021-05-27 |
Медикайн, Инк. |
Соединения, связывающие рецептор il-2
|
|
ES3030707T3
(en)
|
2018-08-13 |
2025-07-01 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
KR20210107714A
(ko)
*
|
2018-12-21 |
2021-09-01 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
인간 인터류킨-2 변이체 또는 이의 유도체
|
|
WO2020160242A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
|
JP7570338B2
(ja)
|
2019-02-15 |
2024-10-21 |
インテグラル・モレキュラー・インコーポレイテッド |
クローディン６抗体及びその使用
|
|
WO2020168024A1
(en)
|
2019-02-15 |
2020-08-20 |
Integral Molecular, Inc. |
Antibodies comprising a common light chain and uses thereof
|
|
WO2020236875A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Therapeutics, Inc. |
Madcam targeted immunotolerance
|
|
CA3141626A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
JP7483857B2
(ja)
|
2019-07-26 |
2024-05-15 |
ビステラ， インコーポレイテッド |
インターロイキン－２作用物質およびその使用
|
|
CA3148505A1
(en)
*
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
WO2021092075A1
(en)
|
2019-11-05 |
2021-05-14 |
Medikine Inc. |
IL-2RβγC BINDING COMPOUNDS
|
|
BR112022008750A2
(pt)
|
2019-11-05 |
2022-07-19 |
Medikine Inc |
Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
|
|
AU2020401357A1
(en)
*
|
2019-12-12 |
2022-07-21 |
Assistance Publique - Hôpitaux De Paris |
Interleukin 2 chimeric constructs
|
|
IL293978A
(en)
*
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
CA3166509A1
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Biased il2 muteins methods and compositions
|
|
JP2023512687A
(ja)
|
2020-02-03 |
2023-03-28 |
メディカイン、インコーポレイテッド |
ＩＬ－７Ｒα結合化合物
|
|
WO2021158623A1
(en)
|
2020-02-03 |
2021-08-12 |
Medikine, Inc. |
IL-7Rαγc BINDING COMPOUNDS
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
US11028132B1
(en)
|
2020-04-07 |
2021-06-08 |
Yitzhak Rosen |
Half-life optimized linker composition
|
|
AU2021272895A1
(en)
|
2020-05-12 |
2022-09-22 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
JP2023526282A
(ja)
|
2020-05-13 |
2023-06-21 |
ボナム セラピューティクス，インク． |
タンパク質複合体の組成物及びその使用方法
|
|
EP4208474A2
(en)
*
|
2020-09-01 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Interleukin-2 muteins and uses thereof
|
|
EP4211149A4
(en)
|
2020-09-09 |
2024-10-09 |
Cue Biopharma, Inc. |
MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
|
|
MX2023004598A
(es)
|
2020-10-23 |
2023-06-29 |
Asher Biotherapeutics Inc |
Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
|
|
AU2021369823A1
(en)
|
2020-10-29 |
2023-06-01 |
Bristol-Myers Squibb Company |
Fusion proteins for the treatment of disease
|
|
US20230398183A1
(en)
|
2020-11-13 |
2023-12-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof
|
|
KR20230129018A
(ko)
|
2020-12-04 |
2023-09-05 |
비스테라, 인크. |
인터류킨-2 작용제를 사용하는 방법
|
|
IL304365B2
(en)
*
|
2021-03-31 |
2025-04-01 |
Hanmi Pharmaceutical Co Ltd |
A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
|
|
US20220323607A1
(en)
|
2021-04-09 |
2022-10-13 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
IL311883A
(en)
|
2021-10-06 |
2024-06-01 |
Assist Publique H?Pitaux De Paris |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
|
WO2023133319A1
(en)
|
2022-01-10 |
2023-07-13 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023172628A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
|
|
US20230372535A1
(en)
|
2022-03-25 |
2023-11-23 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
US11999771B2
(en)
|
2022-04-07 |
2024-06-04 |
Medikine, Inc. |
IL-7Rαγc ligand immunoglobulin fusion proteins
|
|
US20230381277A1
(en)
|
2022-04-08 |
2023-11-30 |
Selecta Biosciences, Inc. |
High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
|
|
CN115322260A
(zh)
*
|
2022-06-13 |
2022-11-11 |
杭州高田生物医药有限公司 |
能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用
|
|
JP2025530309A
(ja)
|
2022-09-12 |
2025-09-11 |
アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） |
自閉症スペクトラム障害の処置に使用するためのインターロイキン－２
|
|
IL319951A
(en)
|
2022-11-30 |
2025-05-01 |
Integral Molecular Inc |
Antibodies targeting claudin 6, including its bispecific formats
|
|
KR20250133750A
(ko)
|
2023-01-09 |
2025-09-08 |
오디세이 테라퓨틱스, 인코포레이티드 |
항-tnfr2 항원-결합 단백질 및 그의 용도
|
|
WO2024229350A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
|
|
WO2024229370A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Compositions and methods for treating gvhd
|
|
WO2024229432A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
|
|
WO2024229380A1
(en)
|
2023-05-03 |
2024-11-07 |
Cartesian Therapeutics, Inc. |
Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
|
|
WO2025217240A1
(en)
|
2024-04-10 |
2025-10-16 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|